This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation
and management of pulmonary sarcoidosis, with each section summarised with key clinical …

Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Rationale: There have been no recent comprehensive studies of the epidemiology of
sarcoidosis in the United States. Changes in health care use have made available access to …

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

Multinational evidence-based World Association of Sarcoidosi... : Current Opinion in Pulmonary
Medicine Multinational evidence-based World Association of Sarcoidosis and Other …

Abstract Uveitis is a frequent (20–50%) and early feature of sarcoidosis. Typical sarcoid
uveitis presents with mutton-fat keratic precipitates, iris nodules, and anterior and posterior …

About half of patients with sarcoidosis will need systemic therapy for their disease. Oral
glucocorticoids are the standard first-line treatment for sarcoidosis. With time, patients might …

Cohort studies of large series of patients with sarcoidosis over a long period of time are
scarce. The aim of this study is to report a 40-year clinical experience of a large series of …